DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for dilated cardiomyopathy 1AA — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDilated cardiomyopathy 1AA maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for dilated cardiomyopathy 1aa is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
actinin alpha 2 (ACTN2) — ACTN2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4D1E · 3.5 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
A 1994 follow-up study of 235 patients aged 16–70 enrolled on a register from 1978 to 1992 reported that two-year and four-year survival rose across three consecutive five-year periods: 73.8% and 53.8% in group 1 (1978–1982, 26 patients), 87.7% and 72.3% in group 2 (1983–1987, 65 patients), and 90.3% and 82.9% in group 3 (1988–1992, 144 patients). The authors noted that patients in later groups were younger and less severely affected, which partly explained the improvement, but the survival curves diverged progressively and the improvement remained significant after stratification for disease severity. A progressively higher proportion of patients were treated with ACE inhibitors and later with beta blockers. In group 2, patients treated with ACE inhibitors showed better survival than those not treated, after stratification for severity. In group 3, beta blockers had a significant additive effect with conventional therapy: four-year survival in patients with mild and moderate-to-severe heart failure treated with beta blockers, usually digitalis and ACE inhibitors, was 90% and 87.5% respectively.
A 2009 study of passive containment surgery using the Acorn CorCap cardiac support device in 20 patients with dilated cardiomyopathy (10 ischemic, 10 idiopathic) reported that all patients survived the surgery, but four died during a mean follow-up of 32 months. The authors found a significant reduction in cardiac dimensions, improved functional capacity, and improved quality of life after surgery, with no significant differences between ischemic and idiopathic groups. They concluded the procedure was safe and simple but called for further studies to identify optimal patient selection criteria, timing of surgery, and long-term effects.
A 2025 literature review on traditional Chinese medicine for dilated cardiomyopathy states that conservative drug therapy is mainly used clinically but is often limited by adverse reactions such as low blood pressure. The review claims traditional Chinese medicine has achieved good therapeutic effects with few adverse reactions, but it does not provide any concrete numbers for survival, response rates, or sample sizes from clinical studies.
What is still missing are large, randomised controlled trials that stratify patients by aetiology, severity, and genetic subtype; long-term outcome data for surgical devices beyond small case series; and any quantitative evidence from traditional Chinese medicine that would allow comparison with the survival figures reported for ACE inhibitors and beta blockers.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Heart · 1994 · 76 citations · open access
Changing mortality in dilated cardiomyopathy
AbstractOBJECTIVE: To analyse the changes in mortality in dilated cardiomyopathy over the past 15 years and to identify the factors that might have influenced survival. DESIGN: Follow up study of 235 patients (aged 16-70) systematically enrolled on a register from 1 January 1978 to 31 December 1992. SETTING: Hospital department of cardiology. PATIENTS: Three groups corresponding to three periods of 5 years: group 1 (diagnosis between 1 January 1978 and 31 December 1982) 26 patients; group 2 (diagnosis between 1 January 1983 and 31 December 1987) 65 patients; and group 3 (diagnosis between 1 January 1988 and 31 December 1992) 144 patients. MAIN OUTCOME MEASURES: Death or heart transplantation. RESULTS: Two and four year survival was 73.8% and 53.8% in group 1, 87.7% and 72.3% in group 2, and 90.3% and 82.9% in group 3 (P = 0.02). During the 15 years of the study period the number of cases increased progressively and the baseline clinical characteristics changed (that is, patients were younger and less severely affected), partly explaining the improvement in survival. None the less, the three mortality curves tended to diverge progressively and the improvement in survival in the different groups was still significant after stratification for the severity of the disease, suggesting that treatment had a sustained effect. A progressively higher proportion of patients were treated with angiotensin converting enzyme (ACE) inhibitors and more recently with beta blockers. In group 2, after stratification for the severity of heart failure, patients who were treated with ACE inhibitors showed a better survival than patients who were not. Furthermore, analysis of group 3 showed that beta blockers had a significant additive effect with conventional therapy both by intention to treat and actual treatment. Four year survival in patients with mild and moderate to severe heart failure treated with beta blockers, and usually digitalis and ACE inhibitors, was respectively 90% and 87.5%. CONCLUSIONS: The improvement in the survival of patients with dilated cardiomyopathy over the past 15 years may be explained by earlier diagnosis, new treatments, and a change in the clinical characteristics of the patients at enrolment.
Cleveland Clinic Journal of Medicine · 2002 · 44 citations
Idiopathic dilated cardiomyopathy: a common but mystifying cause of heart failure.
AbstractWhile researchers try to elucidate the origins of idiopathic dilated cardiomyopathy, clinicians continue to face the challenges of identifying and treating the causes of this condition to improve symptoms and survival. We review classification schemes for dilated cardiomyopathy and the current range of diagnostic and therapeutic options and treatment goals.
Midterm Results of Passive Containment Surgery Using the Acorn Cor Cap⢠Cardiac Support Device in Dilated Cardiomyopathy
AbstractBACKGROUND AND AIM: To evaluate the echocardiographic, functional, and quality of life improving effects of passive containment surgery using the CorCap cardiac support device (CSD; Acorn Cardiovascular Inc., St. Paul, MN, USA) in patients with dilated cardiomyopathy and to investigate the possible differences in ischemic versus idiopathic (i.e., normal angiograms) cardiomyopathy. METHODS: Twenty patients with dilated cardiomyopathy (10 with ischemic and 10 with idiopathic disease) were subjected to application of the cardiac support device, between June 2001 and October 2006. Preoperatively and at follow-up cardiac dimensions, cardiac function, functional capacity, and quality of life were evaluated. Follow-up is complete with a mean follow-up time of 32 +/- 5 months. RESULTS: All patients survived the surgery; four patients died during the follow-up time. Following surgery, there was a significant reduction in cardiac dimensions, improved functional capacity, and improved quality of life. No significant differences could be seen between patients with ischemic versus idiopathic disease. CONCLUSION: Application of the CSD is safe and simple in patients with dilated cardiomyopathy and without any apparent negative effects. Further studies are needed to identify optimal patient selection criteria as well as optimal timing of surgery and to assess the long-term effects of this treatment.
International Journal of General Medicine · 2025 · 0 citations · open access
Traditional Chinese Medicine Treating Dilated Cardiomyopathy: A Literature Review
AbstractDilated cardiomyopathy (DCM), as a difficult problem in modern medical treatment, has become an important cardiovascular disease threatening human beings all over the world with an increasing incidence rate and mortality. Conservative drug therapy is mainly used in clinical practice, but due to unavoidable adverse reactions such as low blood pressure, it is often difficult to achieve satisfactory prognosis. Traditional Chinese medicine has the characteristics of syndrome differentiation and multi-target treatment for DCM, with few adverse reactions and certain advantages. It has achieved good therapeutic effects in clinical practice. Therefore, we summarized and analyzed the clinical evidence and mechanism of traditional Chinese medicine in the treatment of DCM, and combined with the current research status of this disease to analyze the problems and shortcomings, in order to provide more ideas and methods for the treatment of DCM with traditional Chinese medicine.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
